The prescription medicines regulatory reforms include changes that will bring medicines to market sooner in Australia, while maintaining a robust framework for safety, quality and efficacy.

The medical devices regulatory reforms include changes that will provide Australians with earlier access to new medical devices and enhance post-market surveillance.

The complementary medicine regulatory reforms include changes that will create a new approval pathway for listed complementary medicines and increase availability of information to support consumer decisions.

The advertising reforms include changes that will streamline complaints handling, enhance sanctions and penalties available for addressing non-compliant advertising, and abolish the requirement for certain advertisements to be pre-approved.

The post-market monitoring reforms include changes to enhance monitoring and compliance of therapeutic products that are released to market.

Reforms relating to accessing unapproved products include modifications to the Special Access Scheme and Authorised Prescriber scheme to allow streamlined access to certain unapproved therapeutic products.

Reforms to TGA advisory committees include changes that provide greater efficiencies and a reduction in the number of statutory advisory committees that provide independent advice to the TGA.

Further reviews included a review of the Scheduling Policy Framework for medicines and a review of the regulatory framework for low-risk products. A review of all Class I medical devices in the ARTG continues to ensure they meet the requirements for inclusion.

Cross cutting initiatives include developing a support function for small and medium sized enterprises and research institutions to support the growth of the medical technologies, biotechnologies, and pharmaceuticals sector.